Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GNA15 | P30679 | 1/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14045417 | 0.90 | FFAR1 (0.48) | FFAR1SRD5A2FFAR4 | |
| SCHEMBL14565836 | 0.89 | FFAR1 (0.41) | FFAR1SRD5A2FFAR4LMNA | |
| SCHEMBL14045309 | 0.88 | HDAC1 (0.43) | FFAR1 | |
| SCHEMBL14045408 | 0.84 | FFAR1 (0.55) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 | |
| SCHEMBL4596856 | 0.83 | FFAR1 (0.46) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 | |
| SCHEMBL4597108 | 0.82 | FFAR1 (0.56) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 | |
| SCHEMBL14625873 | 0.79 | FFAR1 (0.55) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 | |
| SCHEMBL14115836 | 0.78 | FFAR1 (0.57) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 | |
| SCHEMBL14021677 | 0.78 | FFAR1 (0.57) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4596957 | 0.77 | FFAR1 (0.56) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261981-A1 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2008-07-24 | — | — | US | disclosed |
| US-7399786-B2 | Derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| WO-2007005774-A2 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | GPR119, AADAT, FABP4 | FFAR1 14/4885SRD5A2 2125/4885FFAR4 13/4885 |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | GPR119, AADAT, FABP4 | FFAR1 14/4885SRD5A2 2125/4885FFAR4 13/4885 |
| US-20080261981-A1 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | GPR119, AADAT, FABP4 | FFAR1 14/4885SRD5A2 2125/4885FFAR4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.